Marinus Pharmaceuticals, Inc.
170 Radnor Corporate Center
100 Matson Rd, Suite 500
Radnor, PA 19087
United States
Tel: 484-801-4674
Website: http://www.marinuspharma.com/
184 articles with Marinus Pharmaceuticals, Inc.
-
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
5/18/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June.
-
Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
5/12/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 10, 2022
5/10/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 15 new employees.
-
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
5/5/2022
Marinus Pharmaceuticals, Inc. today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE).
-
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
4/20/2022
Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the first quarter ended March 31, 2022 after the market closes on May 12, 2022.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Apr 18, 2022
4/18/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of an inducement award to one new employee.
-
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
4/14/2022
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY ® (ganaxolone) Phase 3 Marigold Trial Results.
-
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
3/31/2022
Marinus Pharmaceuticals , Inc. today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/21/2022
Marinus Pharmaceuticals, Inc. today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.
-
Ztalmy is Marinus' oral suspension medication for patients ages two years and older who experience seizures linked with cyclin-dependent kinase-like 5 deficiency disorder.
-
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
3/18/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD).
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Mar 15, 2022
3/15/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to three new employees.
-
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here's a look.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Marinus Pharmaceuticals reported that its Phase III RAISE trial of IV ganaxolone for status epilepticus will be delayed, thanks to the pandemic.
-
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
2/22/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.
-
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
2/16/2022
Marinus Pharmaceuticals, Inc. today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021 before the market opens on March 21, 2022.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Feb 10, 2022
2/10/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to six new employees.
-
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
2/3/2022
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update.